Free Trial

Leerink Partnrs Has Positive Outlook of KALV Q3 Earnings

KalVista Pharmaceuticals logo with Medical background

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at Leerink Partnrs raised their Q3 2026 EPS estimates for shares of KalVista Pharmaceuticals in a research report issued on Monday, July 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.54) for the quarter, up from their prior forecast of ($0.56). The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals' Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.48) EPS and FY2027 earnings at ($1.17) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same period last year, the firm earned ($1.07) EPS.

Other equities research analysts have also issued research reports about the stock. Jones Trading restated a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday. JMP Securities raised their target price on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, Leerink Partners raised their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $26.29.

View Our Latest Report on KalVista Pharmaceuticals

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded down $0.48 on Thursday, reaching $15.51. The company's stock had a trading volume of 1,983,930 shares, compared to its average volume of 565,271. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $16.45. The company has a market cap of $771.16 million, a P/E ratio of -4.17 and a beta of -0.04. The company has a 50-day simple moving average of $12.55 and a 200 day simple moving average of $11.19.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,169 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $14.50, for a total transaction of $103,950.50. Following the completion of the sale, the chief executive officer owned 315,074 shares in the company, valued at $4,568,573. This trade represents a 2.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider owned 106,611 shares of the company's stock, valued at $1,262,274.24. The trade was a 2.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,899 shares of company stock valued at $206,176 in the last quarter. 10.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC increased its position in KalVista Pharmaceuticals by 16.6% during the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after purchasing an additional 701,007 shares during the period. Tang Capital Management LLC increased its position in KalVista Pharmaceuticals by 13.2% during the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after purchasing an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. increased its position in KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP increased its position in KalVista Pharmaceuticals by 19.3% during the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares during the period. Finally, Vanguard Group Inc. increased its position in KalVista Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the period.

About KalVista Pharmaceuticals

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Featured Stories

Earnings History and Estimates for KalVista Pharmaceuticals (NASDAQ:KALV)

Should You Invest $1,000 in KalVista Pharmaceuticals Right Now?

Before you consider KalVista Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.

While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines